154287-01-1

Basic information

• Product Name: 1-BUTYLINDOLE-3-CARBOXYLIC ACID
• Synonyms: 1-BUTYLINDOLE-3-CARBOXYLIC ACID;UKRORGSYN-BB BBV-153638
• CAS NO: 154287-01-1
• Molecular Formula: C₁₃H₁₅NO₂
• Molecular Weight: 217.26
• Mol File: 154287-01-1.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-BUTYLINDOLE-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BUTYLINDOLE-3-CARBOXYLIC ACID(154287-01-1)
• EPA Substance Registry System: 1-BUTYLINDOLE-3-CARBOXYLIC ACID(154287-01-1)

Safety Data

• Hazardous Substances Data: 154287-01-1(Hazardous Substances Data)

Usage

Chemical Family

Belongs to the indole family, which is a group of organic compounds that contain a bicyclic structure with a benzene ring fused to a pyrrole ring.

Carboxylic Acid Derivative

It is a carboxylic acid derivative of indole, meaning it has a carboxyl group (-COOH) attached to the indole structure.

Organic Compound

It is a common organic compound found in various natural and synthetic substances.

Potential Applications

Has potential applications in pharmaceutical and industrial fields due to its unique structure and properties.

Building Block

Can be used as a building block in the synthesis of various organic compounds and pharmaceutical drugs.

Biological Activities

Has been studied for its potential biological activities, which may include interactions with biological systems or organisms.

Upstream product

• 858515-87-4 1-butyl-1H-indole-3-carboxylic acid methyl ester 
• 942-24-5 3-methoxycarbonylindole 
• 771-50-6 1H-indole-3-carboxylic acid 
• 542-69-8 1-iodo-butane 
• 60-29-7 diethyl ether 
• 165670-65-5 1-butyl-3-trifluoroacetylindole 
• 119491-09-7 1-(1-butyl)-1H-indole-3-carboxaldehyde 
• 120-72-9 indole 
• 22014-99-9 N-butylindole 

Downstream Products

• 858515-59-0 C₃₅H₄₇N₃O₅ 

Relevant articles and documents

Structure-activity relationships of valine, tert -leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA

Synthetic cannabinoid receptor agonists (SCRAs) remain one the most prevalent classes of new psychoactive substances (NPS) worldwide, and examples are generally poorly characterised at the time of first detection. We have synthesised a systematic library of amino acid-derived indole-, indazole-, and 7-azaindole-3-carboxamides related to recently detected drugs ADB-BUTINACA, APP-BUTINACA and ADB-P7AICA, and characterised these ligands for in vitro binding and agonist activity at cannabinoid receptor subtypes 1 and 2 (CB1 and CB2), and in vivo cannabimimetic activity. All compounds showed high affinity for CB1 (Ki 0.299-538 nM) and most at CB2 (Ki = 0.912-2190 nM), and most functioned as high efficacy agonists of CB1 and CB2 in a fluorescence-based membrane potential assay and a βarr2 recruitment assay (NanoBiT), with some compounds being partial agonists in the NanoBiT assay. Key structure-activity relationships (SARs) were identified for CB1/CB2 binding and CB1/CB2 functional activities; (1) for a given core, affinities and potencies for tert-leucinamides (ADB-) > valinamides (AB-) ? phenylalaninamides (APP-); (2) for a given amino acid side-chain, affinities and potencies for indazoles > indoles ? 7-azaindoles. Radiobiotelemetric evaluation of ADB-BUTINACA, APP-BUTINACA and ADB-P7AICA in mice demonstrated that ADB-BUTINACA and ADB-P7AICA were cannabimimetic at 0.1 mg kg-1 and 10 mg kg-1 doses, respectively, as measured by pronounced decreases in core body temperature. APP-BUTINACA failed to elicit any hypothermic response up to the maximally tested 10 mg kg-1 dose, yielding an in vivo potency ranking of ADB-BUTINACA > ADB-P7AICA > APP-BUTINACA.

NOVEL INDOLE AND PYRROLOPYRIDINE AMIDES

The present invention relates to indole and pyrrolopyridine amide derivatives of formula (I) wherein R1, R 2, R 3, U, V, W, X, Y, Z and ring A are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as orexin receptor antagonists.

Design, synthesis, and biological activity of potent and selective inhibitors of mast cell tryptase

A new series of novel mast cell tryptase inhibitors is reported, which features the use of an indole structure as the hydrophobic substituent on a m-benzylaminepiperidine template. The best members of this series display good in vitro activity and excellent selectivity against other serine proteases.